Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT00158652 Completed - Oral Cancer Clinical Trials

Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC

Start date: March 2000
Phase: Phase 3
Study type: Interventional

This is a multicentric randomized phase III trial comparing conventional radiotherapy with concomitant chemotherapy versus accelerated radiotherapy with concomitant chemotherapy versus very accelerated radiotherapy in patients with stage III-IV head and neck squamous cell carcinoma. The main end point is the event free survival.

NCT ID: NCT00144976 Completed - Clinical trials for Head and Neck Neoplasms

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Start date: October 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.

NCT ID: NCT00139269 Completed - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Start date: February 1998
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the safety and effectiveness of this combination of medications.

NCT ID: NCT00139243 Completed - Clinical trials for Squamous Cell Carcinoma

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Start date: October 1997
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and maximum tolerated dose of the combination taxotere, cisplatin, 5-fluorouracil and leucovorin. We will also preliminarily assess whether the combination is effective in treating squamous cell carcinoma of the head and neck.

NCT ID: NCT00139230 Completed - Clinical trials for Squamous Cell Carcinoma

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Start date: January 1997
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.

NCT ID: NCT00136955 Completed - Clinical trials for Uterine Cervical Neoplasms

Irinotecan Study For Cervical Cancer

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer

NCT ID: NCT00126555 Completed - Clinical trials for Squamous Cell Carcinoma of the Skin

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if giving Iressa (Gefitinib or ZD1839) with surgery and/or radiation will help to control squamous cell carcinoma of the skin. The safety of this treatment will also be studied

NCT ID: NCT00124488 Completed - Cervix Neoplasm Clinical Trials

Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix

Start date: June 2005
Phase: N/A
Study type: Observational

Standard treatment for non-operable cervix cancer is radiation and chemotherapy. This treatment combination can result in significant radiation side-effects involving the bladder, small bowel and rectum. To improve results with radiation/chemotherapy, higher radiation doses have been tried for cervix cancer patients. Results from using higher radiation doses show that cervix tumours may be better controlled, but the radiation side-effects are worsened. Intensity modulated radiotherapy (IMRT) and Tomotherapy are new radiation planning and delivery technologies which may allow for delivery of higher radiation doses with less damage to normal organs. The purpose of this project is to determine whether or not IMRT and/or Tomotherapy technology can produce radiation plans that deliver higher doses of radiation to the tumor and lower doses to normal organs when compared to standard radiation plans. The results from this project will provide the basis for possibly treating future cervix cancer patients with Tomotherapy and providing them with improved cure rates along with decreased rates of radiation side effects. No patients will be treated on this protocol, as the investigators plan to only compare radiation dose calculations from different treatment plans created for test cervix cancer cases. There will be absolutely no patient contact in this protocol.

NCT ID: NCT00122460 Completed - Clinical trials for Head and Neck Cancer

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.

NCT ID: NCT00114283 Completed - Tongue Cancer Clinical Trials

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.